quinine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4523 130-95-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • quinine bisulfate heptahydrate
  • chinine
  • qualaquin
  • quinine
  • quinine sulfate
An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood.
  • Molecular weight: 324.42
  • Formula: C20H24N2O2
  • CLOGP: 2.79
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 45.59
  • ALOGS: -2.99
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.50 g O
1.50 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 111.10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 12 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 71.07 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 1.80 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.30 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 11 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Aug. 12, 2005 FDA MUTUAL PHARM CO INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 229.86 14.59 161 13620 72357 63402884
Labile blood pressure 169.33 14.59 45 13736 1744 63473497
Lipase increased 119.13 14.59 53 13728 9847 63465394
Somatic symptom disorder 89.12 14.59 30 13751 2630 63472611
Hepatic ischaemia 88.78 14.59 22 13759 642 63474599
Sacroiliitis 86.94 14.59 31 13750 3226 63472015
Haematemesis 83.59 14.59 62 13719 30350 63444891
Hepatorenal syndrome 81.75 14.59 26 13755 1906 63473335
Hepatic failure 64.64 14.59 57 13724 35599 63439642
Toxicity to various agents 62.37 14.59 154 13627 247096 63228145
Coronary artery disease 61.19 14.59 53 13728 32324 63442917
Drug ineffective 58.12 14.59 86 13695 1044679 62430562
Muscle relaxant therapy 56.84 14.59 12 13769 167 63475074
Cognitive disorder 56.41 14.59 65 13716 55750 63419491
Renal failure 55.52 14.59 95 13686 117557 63357684
Sedation complication 54.02 14.59 35 13746 13787 63461454
Coagulopathy 50.08 14.59 39 13742 20505 63454736
Hyponatraemia 47.16 14.59 86 13695 111814 63363427
Electrocardiogram QT prolonged 46.68 14.59 61 13720 59469 63415772
Hypovolaemia 46.63 14.59 29 13752 10644 63464597
Pancreatitis 46.03 14.59 55 13726 49000 63426241
Drug hypersensitivity 44.26 14.59 158 13623 310529 63164712
Duodenal ulcer 44.15 14.59 25 13756 7731 63467510
Thrombotic microangiopathy 41.90 14.59 27 13754 10534 63464707
Gastrointestinal haemorrhage 41.54 14.59 68 13713 81108 63394133
Mood altered 40.37 14.59 30 13751 14713 63460528
Drug intolerance 40.05 14.59 9 13772 308652 63166589
Creatinine renal clearance decreased 39.83 14.59 31 13750 16277 63458964
Blood calcium decreased 39.59 14.59 38 13743 26413 63448828
Infusion related reaction 39.02 14.59 4 13777 245517 63229724
Fear of eating 37.76 14.59 10 13771 382 63474859
Product dose omission issue 36.77 14.59 4 13777 234309 63240932
Post procedural haemorrhage 35.71 14.59 22 13759 7942 63467299
Fall 35.06 14.59 173 13608 392161 63083080
Off label use 34.98 14.59 58 13723 674404 62800837
Hiccups 33.59 14.59 14 13767 2217 63473024
Depressed level of consciousness 33.11 14.59 53 13728 62025 63413216
Coronary artery bypass 32.78 14.59 14 13767 2355 63472886
Orthostatic hypotension 31.41 14.59 39 13742 36121 63439120
Abdominal discomfort 30.22 14.59 16 13765 320869 63154372
Rheumatoid arthritis 29.87 14.59 9 13772 253810 63221431
Synovitis 29.81 14.59 3 13778 186915 63288326
Retinal toxicity 29.79 14.59 11 13770 1264 63473977
Rhabdomyolysis 28.36 14.59 41 13740 43910 63431331
Myocardial ischaemia 28.31 14.59 23 13758 12836 63462405
Cinchonism 27.51 14.59 4 13777 3 63475238
Fatigue 27.45 14.59 100 13681 887928 62587313
Hepatic enzyme increased 26.03 14.59 6 13775 202322 63272919
Blood sodium decreased 25.77 14.59 29 13752 24223 63451018
Nail infection 25.60 14.59 12 13769 2511 63472730
Purpura senile 25.58 14.59 8 13773 555 63474686
Left ventricular dysfunction 25.47 14.59 21 13760 11967 63463274
Tarsal tunnel syndrome 25.42 14.59 8 13773 566 63474675
Vestibular disorder 25.03 14.59 10 13771 1421 63473820
Abdominal rigidity 24.87 14.59 11 13770 2013 63473228
Swollen tongue 24.73 14.59 34 13747 34766 63440475
Vascular injury 24.66 14.59 9 13772 1001 63474240
Constipation 24.34 14.59 105 13676 224838 63250403
Oral cavity fistula 24.21 14.59 8 13773 662 63474579
Hypotension 24.15 14.59 120 13661 272484 63202757
Salivary gland enlargement 23.60 14.59 7 13774 406 63474835
Optic ischaemic neuropathy 22.99 14.59 9 13772 1213 63474028
Exostosis of jaw 22.52 14.59 9 13772 1280 63473961
Therapeutic product effect decreased 22.45 14.59 7 13774 193180 63282061
Acute kidney injury 21.96 14.59 114 13667 263301 63211940
Cerebral artery occlusion 21.94 14.59 8 13773 887 63474354
Sedation 21.89 14.59 34 13747 38775 63436466
Drug interaction 21.82 14.59 103 13678 229028 63246213
Discomfort 21.45 14.59 5 13776 167369 63307872
Hepatocellular injury 21.36 14.59 28 13753 27353 63447888
Eczema asteatotic 21.29 14.59 6 13775 290 63474951
Poor peripheral circulation 21.11 14.59 12 13769 3737 63471504
Exposed bone in jaw 21.01 14.59 11 13770 2914 63472327
Product use issue 20.74 14.59 11 13770 220509 63254732
Muscle necrosis 20.29 14.59 7 13774 661 63474580
Arthropathy 20.26 14.59 13 13768 234779 63240462
Hand deformity 19.97 14.59 5 13776 159452 63315789
Pain 19.93 14.59 88 13693 740540 62734701
Cerebrovascular accident 19.87 14.59 60 13721 107964 63367277
Haemolytic uraemic syndrome 19.67 14.59 10 13771 2493 63472748
Resorption bone increased 19.20 14.59 8 13773 1266 63473975
Arthralgia 18.31 14.59 63 13718 569647 62905594
Myocardial infarction 17.92 14.59 55 13726 99838 63375403
Ulcer 17.79 14.59 25 13756 26082 63449159
Adrenal mass 17.64 14.59 7 13774 977 63474264
Hyperkalaemia 17.18 14.59 37 13744 54166 63421075
Multiple organ dysfunction syndrome 17.15 14.59 38 13743 56714 63418527
Gastrointestinal disorder 16.66 14.59 4 13777 131235 63344006
Nephrogenic systemic fibrosis 16.49 14.59 11 13770 4545 63470696
Sinusitis 16.42 14.59 15 13766 226638 63248603
Injection site pain 16.39 14.59 4 13777 129796 63345445
Joint swelling 16.17 14.59 29 13752 327637 63147604
Swelling 15.84 14.59 22 13759 275356 63199885
Cardiac arrest 15.72 14.59 50 13731 92495 63382746
Disseminated intravascular coagulation 15.67 14.59 20 13761 19031 63456210
Vaginal discharge 15.27 14.59 14 13767 9184 63466057
Sequestrectomy 15.24 14.59 6 13775 820 63474421
International normalised ratio increased 15.07 14.59 32 13749 46393 63428848
Chest pain 15.00 14.59 89 13692 215870 63259371
Gastritis 14.85 14.59 28 13753 37275 63437966
Alopecia 14.82 14.59 32 13749 337504 63137737
Hypomagnesaemia 14.59 14.59 24 13757 28713 63446528

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 1104.48 17.01 500 7173 98596 34850662
Toxicity to various agents 280.34 17.01 277 7396 200085 34749173
Poisoning 84.68 17.01 45 7628 12181 34937077
Exposure via ingestion 58.91 17.01 21 7652 2160 34947098
Cinchonism 54.37 17.01 8 7665 7 34949251
Intentional product misuse 50.56 17.01 56 7617 45555 34903703
Compartment syndrome 45.45 17.01 19 7654 2999 34946259
Electrocardiogram U wave present 42.79 17.01 7 7666 19 34949239
Atrioventricular block 35.24 17.01 22 7651 8041 34941217
Toxic neuropathy 29.79 17.01 9 7664 550 34948708
Urine sodium decreased 29.09 17.01 7 7666 178 34949080
Mouth swelling 29.01 17.01 12 7661 1844 34947414
Drug ineffective 27.66 17.01 36 7637 456715 34492543
Agitated depression 26.86 17.01 7 7666 248 34949010
Hypomagnesaemia 26.23 17.01 28 7645 21823 34927435
Nephrogenic systemic fibrosis 25.64 17.01 14 7659 3991 34945267
Respiratory arrest 25.31 17.01 31 7642 28012 34921246
Lower respiratory tract infection 23.88 17.01 32 7641 31605 34917653
Cerebral malaria 22.27 17.01 3 7670 0 34949258
Cardiac arrest 21.83 17.01 58 7615 96101 34853157
Off label use 21.55 17.01 37 7636 419487 34529771
Unresponsive to stimuli 20.98 17.01 28 7645 27541 34921717
Confusional state 20.63 17.01 74 7599 144086 34805172
Infected skin ulcer 20.48 17.01 9 7664 1604 34947654
Muscle spasms 19.89 17.01 48 7625 74953 34874305
Tendonitis 19.24 17.01 16 7657 9124 34940134
Increased bronchial secretion 19.15 17.01 9 7664 1872 34947386
Cutaneous extramedullary haemopoiesis 18.98 17.01 3 7670 6 34949252
Lethargy 18.84 17.01 33 7640 41089 34908169
Body mass index decreased 18.43 17.01 5 7668 207 34949051
Alveolar proteinosis 18.28 17.01 6 7667 481 34948777
Blood sodium decreased 18.06 17.01 20 7653 16231 34933027
Skin induration 18.01 17.01 9 7664 2142 34947116
Blindness transient 17.71 17.01 9 7664 2217 34947041
Hypocalcaemia 17.46 17.01 24 7649 24265 34924993

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 1252.31 13.85 663 18831 162028 79562866
Toxicity to various agents 281.48 13.85 424 19070 421116 79303778
Thrombotic microangiopathy 164.97 13.85 86 19408 20083 79704811
Labile blood pressure 149.35 13.85 44 19450 2209 79722685
Somatic symptom disorder 87.01 13.85 30 19464 2507 79722387
Cinchonism 80.53 13.85 12 19482 10 79724884
Drug ineffective 79.18 13.85 89 19405 1080824 78644070
Sacroiliitis 79.06 13.85 31 19463 3723 79721171
Poisoning 75.90 13.85 57 19437 25215 79699679
Hepatic ischaemia 74.89 13.85 22 19472 1093 79723801
Haematemesis 67.10 13.85 73 19421 52191 79672703
Exposure via ingestion 63.12 13.85 29 19465 5145 79719749
Hepatorenal syndrome 62.02 13.85 27 19467 4222 79720672
Muscle relaxant therapy 55.48 13.85 12 19482 166 79724728
Off label use 53.83 13.85 87 19407 907128 78817766
Microangiopathic haemolytic anaemia 52.15 13.85 18 19476 1509 79723385
Hyponatraemia 50.66 13.85 125 19369 177723 79547171
Product dose omission issue 48.58 13.85 3 19491 247534 79477360
Sedation complication 46.29 13.85 35 19459 15634 79709260
Cognitive disorder 45.85 13.85 70 19424 69856 79655038
Acute kidney injury 44.04 13.85 246 19248 519158 79205736
Agitated depression 40.24 13.85 11 19483 420 79724474
Fall 40.03 13.85 229 19265 487400 79237494
Intentional product misuse 39.71 13.85 78 19416 95087 79629807
Rhabdomyolysis 38.83 13.85 81 19413 103050 79621844
Atrioventricular block 38.49 13.85 30 19464 14011 79710883
Blood calcium decreased 38.33 13.85 43 19451 31776 79693118
Coronary artery disease 36.67 13.85 61 19433 65413 79659481
Depressed level of consciousness 36.49 13.85 76 19418 96576 79628318
Electrocardiogram QT prolonged 36.40 13.85 73 19421 90313 79634581
Hypovolaemia 36.39 13.85 32 19462 17659 79707235
Coagulopathy 35.64 13.85 44 19450 35962 79688932
Blood sodium decreased 35.13 13.85 42 19452 33213 79691681
Fear of eating 34.72 13.85 10 19484 463 79724431
Retinal toxicity 34.53 13.85 13 19481 1398 79723496
Mood altered 34.17 13.85 31 19463 17816 79707078
Compartment syndrome 34.07 13.85 19 19475 5063 79719831
Nephrogenic systemic fibrosis 33.24 13.85 20 19474 6140 79718754
Hepatic failure 32.91 13.85 56 19438 61156 79663738
Renal failure 32.91 13.85 116 19378 200852 79524042
Swollen tongue 32.81 13.85 46 19448 42524 79682370
Creatinine renal clearance decreased 32.51 13.85 31 19463 18971 79705923
Duodenal ulcer 32.46 13.85 29 19465 16340 79708554
Cardiac arrest 32.30 13.85 104 19390 171992 79552902
Hypomagnesaemia 32.22 13.85 48 19446 46863 79678031
Rheumatoid arthritis 32.18 13.85 6 19488 208464 79516430
Infusion related reaction 30.84 13.85 9 19485 230228 79494666
Electrocardiogram U wave present 30.53 13.85 7 19487 128 79724766
Respiratory arrest 28.79 13.85 51 19443 57499 79667395
Post procedural haemorrhage 28.55 13.85 25 19469 13719 79711175
Exposed bone in jaw 27.96 13.85 15 19479 3705 79721189
Contraindicated product administered 27.89 13.85 3 19491 157535 79567359
Hypocalcaemia 27.27 13.85 46 19448 49878 79675016
Fatigue 27.22 13.85 126 19368 929601 78795293
Hepatic enzyme increased 26.64 13.85 6 19488 182604 79542290
Synovitis 26.35 13.85 3 19491 150731 79574163
Lethargy 26.22 13.85 60 19434 81232 79643662
Gastrointestinal haemorrhage 25.68 13.85 87 19407 147632 79577262
Purpura senile 25.12 13.85 8 19486 522 79724372
Tarsal tunnel syndrome 25.03 13.85 8 19486 528 79724366
Drug intolerance 24.94 13.85 17 19477 264102 79460792
Nail infection 24.81 13.85 12 19482 2387 79722507
Treatment failure 24.08 13.85 6 19488 170480 79554414
Prescription drug used without a prescription 23.97 13.85 14 19480 4071 79720823
Toxic neuropathy 23.88 13.85 9 19485 971 79723923
Myocardial ischaemia 23.37 13.85 30 19464 25489 79699405
Vascular injury 22.70 13.85 9 19485 1112 79723782
Salivary gland enlargement 22.56 13.85 7 19487 419 79724475
Cerebral malaria 21.95 13.85 3 19491 0 79724894
Exostosis of jaw 21.73 13.85 9 19485 1245 79723649
Cerebrovascular accident 21.53 13.85 85 19409 155207 79569687
Drug interaction 21.43 13.85 174 19320 415009 79309885
Liver function test abnormal 21.24 13.85 48 19446 64427 79660467
Cardiovascular disorder 21.10 13.85 24 19470 18001 79706893
Orthostatic hypotension 21.00 13.85 44 19450 56120 79668774
Therapeutic product effect decreased 20.88 13.85 7 19487 163856 79561038
Unresponsive to stimuli 20.04 13.85 43 19451 55745 79669149
Poor peripheral circulation 19.98 13.85 12 19482 3671 79721223
Blindness transient 19.50 13.85 13 19481 4763 79720131
Bradycardia 19.44 13.85 75 19419 135482 79589412
Abdominal rigidity 19.23 13.85 11 19483 3077 79721817
Oral cavity fistula 19.08 13.85 7 19487 700 79724194
Ulcer 18.24 13.85 29 19465 29943 79694951
Left ventricular dysfunction 18.10 13.85 23 19471 19338 79705556
Product use issue 17.88 13.85 15 19479 209807 79515087
Skin induration 17.72 13.85 12 19482 4513 79720381
Melaena 17.52 13.85 43 19451 60847 79664047
Injection site pain 17.52 13.85 5 19489 129833 79595061
Confusional state 17.33 13.85 135 19359 317862 79407032
Resorption bone increased 17.16 13.85 8 19486 1467 79723427
Optic ischaemic neuropathy 16.98 13.85 10 19484 2951 79721943
Coronary artery bypass 16.72 13.85 13 19481 6049 79718845
Sinusitis 16.63 13.85 14 19480 195487 79529407
International normalised ratio increased 16.61 13.85 52 19442 84669 79640225
Deafness 16.60 13.85 23 19471 21014 79703880
Hiccups 16.47 13.85 16 19478 10015 79714879
Plasmodium falciparum infection 16.42 13.85 4 19490 96 79724798
Vaginal discharge 16.36 13.85 14 19480 7449 79717445
Eczema asteatotic 16.36 13.85 6 19488 600 79724294
Weight increased 15.99 13.85 27 19467 277359 79447535
Cerebral artery occlusion 15.98 13.85 8 19486 1714 79723180
Vestibular disorder 15.97 13.85 9 19485 2446 79722448
Myocardial infarction 15.39 13.85 87 19407 184042 79540852
Lip swelling 15.23 13.85 32 19462 40879 79684015
Hallucination, visual 15.09 13.85 28 19466 32701 79692193
Alveolar proteinosis 14.82 13.85 6 19488 783 79724111
Mouth swelling 14.60 13.85 12 19482 6039 79718855
Sequestrectomy 14.31 13.85 6 19488 856 79724038
Muscle necrosis 14.20 13.85 7 19487 1451 79723443
Pericarditis 14.09 13.85 4 19490 104232 79620662
Intentional product use issue 14.07 13.85 10 19484 152102 79572792
Blindness 13.99 13.85 25 19469 28358 79696536
Neutrophil count decreased 13.87 13.85 3 19491 93956 79630938

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M09AA72 MUSCULO-SKELETAL SYSTEM
OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
Quinine and derivatives
ATC P01BC01 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ANTIPROTOZOALS
ANTIMALARIALS
Methanolquinolines
FDA EPC N0000175482 Antimalarial
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000962 Antimalarials
MeSH PA D000977 Antiparasitic Agents
MeSH PA D000981 Antiprotozoal Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D009125 Muscle Relaxants, Central
MeSH PA D009465 Neuromuscular Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
CHEBI has role CHEBI:38068 antimalarials
CHEBI has role CHEBI:51371 muscle relaxants

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Falciparum malaria indication 62676009 DOID:14067
Chloroquine Resistant Plasmodium Falciparum Malaria indication
Babesiosis off-label use 21061004 DOID:9643
Atrial flutter contraindication 5370000
Torsades de pointes contraindication 31722008
End stage renal disease contraindication 46177005 DOID:784
Atrial fibrillation contraindication 49436004 DOID:0060224
Neuromuscular block, function contraindication 55394004
Black water fever contraindication 56625005 DOID:14068
Acute nephropathy contraindication 58574008
Optic neuritis contraindication 66760008 DOID:1210
Thrombotic thrombocytopenic purpura contraindication 78129009 DOID:10772
Myasthenia gravis contraindication 91637004 DOID:437
Hemolytic uremic syndrome contraindication 111407006 DOID:12554
Anemia due to enzyme deficiency contraindication 111577008
Prolonged QT interval contraindication 111975006
Disease of liver contraindication 235856003 DOID:409
Hypoglycemic disorder contraindication 237630007
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Congenital long QT syndrome contraindication 442917000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.44 acidic
pKa2 8.02 Basic
pKa3 4.1 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Potassium voltage-gated channel subfamily H member 2 Ion channel WOMBAT-PK
Multidrug resistance protein 1 Transporter Ki 4.92 CHEMBL
Hemoglobin subunit alpha Secreted WOMBAT-PK
Potassium voltage-gated channel subfamily B member 2 Ion channel BLOCKER IC50 4.90 IUPHAR
Solute carrier family 22 member 1 Transporter IC50 4.29 CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 5.36 CHEMBL
Equilibrative nucleoside transporter 4 Transporter INHIBITOR Ki 4.57 IUPHAR

External reference:

IDSource
D08460 KEGG_DRUG
6183-68-2 SECONDARY_CAS_RN
6119-70-6 SECONDARY_CAS_RN
4018620 VANDF
4019926 VANDF
CHEBI:15854 CHEBI
QI9 PDB_CHEM_ID
CHEMBL170 ChEMBL_ID
CHEMBL2146083 ChEMBL_ID
CHEMBL2359966 ChEMBL_ID
2510 IUPHAR_LIGAND_ID
DB00468 DRUGBANK_ID
A7V27PHC7A UNII
647128 RXNORM
5023 MMSL
5405 MMSL
84102 MMSL
d00366 MMSL
002934 NDDF
002935 NDDF
373497008 SNOMEDCT_US
47065008 SNOMEDCT_US
47857006 SNOMEDCT_US
C0034417 UMLSCUI
D011803 MESH_DESCRIPTOR_UI
3034034 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Quinine Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0093-3002 CAPSULE 324 mg ORAL ANDA 31 sections
Quinine Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0093-3002 CAPSULE 324 mg ORAL ANDA 31 sections
Qualaquin HUMAN PRESCRIPTION DRUG LABEL 1 13310-153 CAPSULE 324 mg ORAL NDA 32 sections
QUALAQUIN HUMAN PRESCRIPTION DRUG LABEL 1 16590-595 CAPSULE 324 mg ORAL NDA 32 sections
Qualaquin HUMAN PRESCRIPTION DRUG LABEL 1 49708-153 CAPSULE 324 mg ORAL NDA 32 sections
QUININE SULFATE HUMAN PRESCRIPTION DRUG LABEL 1 50742-238 CAPSULE 324 mg ORAL ANDA 21 sections
Quinine Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 53489-700 CAPSULE 324 mg ORAL NDA authorized generic 32 sections
Quinine Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 65162-811 CAPSULE 324 mg ORAL ANDA 20 sections
Quinine Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 65162-811 CAPSULE 324 mg ORAL ANDA 20 sections
Quinine Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 68084-947 CAPSULE 324 mg ORAL NDA authorized generic 31 sections
Quinine Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 68084-947 CAPSULE 324 mg ORAL NDA authorized generic 31 sections
Quinine Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 68084-947 CAPSULE 324 mg ORAL NDA authorized generic 31 sections
QUININE SULFATE HUMAN PRESCRIPTION DRUG LABEL 1 68180-560 CAPSULE 324 mg ORAL ANDA 20 sections
QUININE SULFATE HUMAN PRESCRIPTION DRUG LABEL 1 68180-560 CAPSULE 324 mg ORAL ANDA 20 sections